|
1.Benaud, C., Dickson, R. B. & Lin, C. Y. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem 268, 1439-47 (2001).
2.Benaud, C. et al. Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem 277, 10539-46 (2002).
3.Benaud, C. M., Oberst, M., Dickson, R. B. & Lin, C. Y. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 19, 639-49 (2002).
4.Bhatt, A. S. et al. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol Chem 384, 257-66 (2003).
5.Crew, K. D. & Neugut, A. I. Epidemiology of gastric cancer. World J Gastroenterol 12, 354-62 (2006).
6.Denda, K., Shimomura, T., Kawaguchi, T., Miyazawa, K. & Kitamura, N. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J Biol Chem 277, 14053-9 (2002).
7.Everett, S. M. & Axon, A. T. Early gastric cancer: disease or pseudo-disease? Lancet 351, 1350-2 (1998).
8.Hoang, C. D. et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125, 1843-52 (2004).
9.Johnson, M. D., Oberst, M. D., Lin, C. Y. & Dickson, R. B. Possible role of matriptase in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 3, 331-8 (2003).
10.Kang, J. Y. et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63, 1101-5 (2003).
11.Kataoka, H., Miyata, S., Uchinokura, S. & Itoh, H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 22, 223-36 (2003).
12.Lee, J. W. et al. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 36, 626-33 (2005).
13.Lee, M. S., Kiyomiya, K., Benaud, C., Dickson, R. B. & Lin, C. Y. Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. Am J Physiol Cell Physiol 288, C932-41 (2005).
14.Lee, S. L., Dickson, R. B. & Lin, C. Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275, 36720-5 (2000).
15.Lin, C. Y., Anders, J., Johnson, M. & Dickson, R. B. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 274, 18237-42 (1999).
16.Lin, C. Y., Anders, J., Johnson, M., Sang, Q. A. & Dickson, R. B. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 274, 18231-6 (1999).
17.Lin, C. Y. et al. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem 272, 9147-52 (1997).
18.List, K. et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21, 3765-79 (2002).
19.List, K. et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 19, 1934-50 (2005).
20.List, K. et al. Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J Cell Biol 163, 901-10 (2003).
21.Oberst, M. et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 158, 1301-11 (2001).
22.Oberst, M. D. et al. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol 289, C462-70 (2005).
23.Oberst, M. D. et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 8, 1101-7 (2002).
24.Oberst, M. D. et al. Characterization of matriptase expression in normal human tissues. J Histochem Cytochem 51, 1017-25 (2003).
25.Pyne, S. & Pyne, N. J. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 349, 385-402 (2000).
26.Saleem, M. et al. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15, 217-27 (2006).
27.Santin, A. D. et al. The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 98, 1898-904 (2003).
28.Shi, Y. E. et al. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 53, 1409-15 (1993).
29.Tanimoto, H. et al. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 22, 104-14 (2001).
30. 吳邱文等主編 胃癌之診斷及治療第一版2000年.
31. 日本胃癌協會編 Japanese Classification of Gastric Carcinoma, June 1999, 13th Edition
|